Plasmapheresis and Intravenous Immunoglobin: Clinical Uses, Potential Complications and Long-Term Health Effects

Rossana Allegro (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED038000

Clear

$192.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Plasmapheresis is a therapeutic tool used to treat a wide range of disease processes, and in which the priority aim is to ensure sufficient plasma exchange to reduce or eliminate symptoms resulting from the action of pathogenic elements vehiculized in the plasma. Scientific selective apheresis with principles of evidence-based medicine involves the application of one of the oldest therapeutic modalities (bleeding), widely used between the fourth century B.C. and the second industrial revolution. This book provides information on the use of plasmaoheresis during pregnancy; therapeutic use of autologous plasma for the treatment of dry eye disease; and therapeutic plasma exchange in the neurological setting. It also discusses intravenous immunoglobulins. During the past decades intravenous immunoglobulins (IVIG) have gained more and more popularity for the treatment of a wide range of diseases and conditions.

This treatment is extensively used in immune deficits, autoimmune thrombocytopenia, Kawasaki’s disease, for the prevention of infectious complications due to hypogammaglobulinaemia secondary to myeloma, chronic lymphatic leukaemia and post-bone marrow and stem cell transplantation, in Guillain-Barre syndrome, etc. IV-Ig is obtained from the plasma of healthy blood donors and contains normal, polyclonal, polyspecific immunoglobins (Ig), mostly consisting of intact IgG. These antibodies are directed against non-self antigens, self-antigens (natural autoantibodies), and other antibodies (idiotypic antibodies). The administration of intravenous immunoglobulin (IVIG) is generally safe and well tolerated. However, the treatment of autoimmune disorders usually requires high dose therapy (1-2 g/kg) that may result in a greater frequency of side effects and adverse events. This book discusses several topics including the clinical application of intravenous immunoglobulins in autoimmune mediated ocular inflammatory diseases; complications of intravenous immunoglobulin therapy; clinical uses; and side effects. (Imprint: Nova Biomedical )

Preface

Chapter 1 - Clinical Application of Intravenous Immunoglobulins in Autoimmune Mediated Ocular Inflammatory Diseases (pp. 1-20)
Swetha Dhanireddy, MD, Jamie Lynne Metzinger, MS, MPH and C. Stephen Foster, MD, FACS, FACR (Massachusetts Eye Research and Surgery Institution, Cambridge, MA, USA, and others)

Chapter 2 - Complications of Intravenous Immunoglobulin Therapy (pp. 21-38)
Joseph Kahwaji, MD, MPH, Jua Choi, PharmD, Stanley Jordan, MD and Ashley Vo, PharmD (Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA)

Chapter 3 - Use of Plasma Replacement Therapy during Pregnancy (pp. 39-106)
Ernesto González-Mesa, PhD, José M. González-Mesa, MD, Pedro Azumendi-Gómez, Laura Baños Cándenas, MD, María José Benítez-Marín, Ana Guzmán-León, MD, Aurelia Marsac, MD and José Herrera-Peral, PhD (Department of Obstetrics and Gynecology, University of Málaga, Spain and others)

Chapter 4 - Effects of IVIg on T Cell Functions (pp. 107-134)
Lauriane Padet and Renée Bazin (Department of Research and Development, Héma-Québec, Québec, Canada, and others)
Free Download Available

Chapter 5 - Intravenous Immunoglobin (IVIG): Clinical Uses in Autoimmune Disorders As Especially Eosinophilic Granulomatosis with Polyangiitis, Potential Complications and Long-Term Efficacy (pp. 135-158)
Naomi Tsurikisawa, MD, Hiroshi Saito, PhD, Chiyako Oshikata, MD and Kazuo Akiyama (Departments of Allergy and Respirology and the Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sakuradai, Minami-ku Sagamihara, Kanagawa, Japan)

Chapter 6 - Therapy with Immunoglobulin in Patients with Acute Myocarditis (pp. 159-168)
Chiharu Kishimoto (Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan)

Chapter 7 - Therapeutic Use of Autologous Plasma for the Treatment of Dry Eye Disease (pp. 169-190)
Beau J. Fenner and Louis Tong (Duke-NUS Graduate Medical School, Singapore, Singapore Eye Research Institute, Singapore National Eye Centre)

Chapter 8 - Side Effects of Intravenous Immunoglobulins (IVIG) (pp. 191-204)
Krasimir Nikolov, Milena Nikolova–Vlahova and Marta Baleva (University Hospital Alexandrovska, Medical University, Sofia, Bulgaria)

Chapter 9 - Therapeutic Plasma Exchange in the Neurological Setting: Some Special Cases (pp. 205-210)
Karin Janssen van Doorn, MD and Sanne Vellinga, MD (Department of Nephrology-Hypertension, Antwerp University Hospital, Belgium, and others)

Index

You have not viewed any product yet.